Clinical genetics research into the variability of response to anti-VEGF treatment suggests common gene variants may have a limited contribution
Research led by a team at the Radboud University Medical Center in Nijmegen, the Netherlands, have shown that the response to anti-VEGF medication may arise from a complexity of interactions, rather than a small defined number of common genetic variants. The clinical genetics research involved a genome-wide association study (GWAS) of 678 nAMD patients revealing […]Read full story
Association of anticholinergic drug exposure with increased risk of late stage AMD uncovered in French population
A new French multi-centre case control study conducted in four French ophthalmologic centers in Montpellier and Nimes has reported an association of late AMD (age-related macular degeneration) with increasing exposure to anti-cholinergic drugs (ACDs) for at least 3 months before AMD diagnosis. As increased age is a significant risk factor for AMD, and the use […]Read full story
New epidemiology study shows a reduction in prevalence of vision loss and vision impairment in high-income countries.
A new epidemiological study in vision loss and vision impairment, conducted by the Vision Loss Expert Group of the Global Burden of Disease (GBD) Study, and led by Professor Rupert Bourne, of the School of Medicine, Anglia Ruskin University, Cambridge, has shown a decrease in the prevalence of blindness and moderate and severe vision impairment […]Read full story